Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108301 | 0.84 | KDM4E (0.41) | HTTEGFRPDGFRBKDRMAPT | |
| SCHEMBL1685039 | 0.83 | EGFR (0.52) | SMN1; SMN2HTTADORA2AEGFRPDGFRB | |
| SCHEMBL3113119 | 0.82 | MAOA (0.42) | SMN1; SMN2HTTADORA2AEGFRPDGFRB | |
| Hydrochloric Acid SCHEMBL1685079 | 0.82 | EGFR (0.51) | HTTADORA2AEGFRPDGFRBKDR | |
| SCHEMBL3106594 | 0.81 | MAPT (0.42) | HTTMEN1NPC1MAPTRAB9A | |
| SCHEMBL3106572 | 0.80 | KDM4E (0.46) | SMN1; SMN2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL3121144 | 0.79 | POLB (0.38) | SMN1; SMN2HTTADORA2AMEN1MAPT | |
| SCHEMBL3113247 | 0.79 | ALDH1A1 (0.54) | HTTADORA2AMEN1NPC1MAPT | |
| SCHEMBL3115622 | 0.78 | GBA1 (0.46) | SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL2262116 | 0.75 | EGFR (0.43) | SMN1; SMN2EGFRPDGFRBKDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258145-B2 | Method of treating brain cancer | MYREXIS, INC. (US) | 2012-09-04 | — | — | US | claimed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2008-02-28 | — | — | US | claimed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | claimed |
| JP-2007524637-A | — | — | 2007-08-30 | — | — | JP | claimed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | claimed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8258145-B2 | Method of treating brain cancer | MYREXIS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | IGF1R 4205/4885ACP1 562/4885PTGER4 4044/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | IGF1R 4163/4885ACP1 649/4885PTGER4 3974/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | IGF1R 4198/4885ACP1 677/4885PTGER4 3993/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | IGF1R 4205/4885ACP1 562/4885PTGER4 4044/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | IGF1R 4205/4885ACP1 562/4885PTGER4 4044/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | IGF1R 4205/4885ACP1 562/4885PTGER4 4044/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | IGF1R 4205/4885ACP1 562/4885PTGER4 4044/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | IGF1R 4205/4885ACP1 562/4885PTGER4 4044/4885 |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | CASP3, CASP7, BAD | IGF1R 3303/4885ACP1 1256/4885PTGER4 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.